The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
Autologous bone marrow-derived mesenchymal cells will be injected into patients diagnosed
 with premature ovarian failure
MSCs in passage-2 culture will be washed with PBS and detached with trypsin/EDTA (0.25%).
 After that, the cells will be suspended at a density of 20×106 cells/ 2 ml normal saline and
 loaded into 3 ml sterile syringes.

 The cells should be infused within 2 hours of release. Tests and follow up are to be monthly.
Inclusion Criteria:

 1. Signed and dated informed consent

 2. Married female, 18-38 years old

 3. Diagnosis of premature ovarian insufficiency: At least two menopausal FSH levels (≥ 20
 IU/L) and/or Primary or secondary amenorrhea at least for 6 months

 4. Evidence of low ovarian reserve defined as: AMH < _0.3 ng/ML & FSH >20 IU/L, AFC < 4,
 and/or failure of prior attempts of assisted reproductive techniques due to limited
 ovarian response (poor responder).

 5. Normal karyotype 46, XX.

 6. Presence of at least one ovary

 7. Normal thyroid function as evidence by normal serum Thyroid Stimulating Hormone (TSH)
 levels.

 8. Agree to report any pregnancy to the research staff immediately.

 9. Cooperative patient

 10. Negative for infectious panel (HIV, HBV, HCV, and VDRL)

 Exclusion Criteria:

 1. Currently breast-feeding

 2. Has a history of, or evidence of current malignancy

 3. Major mental health disorder that precludes participation in the study

 4. Current or recent (within the past 2 weeks) use of the following medications: Oral or
 systemic corticosteroids, Hormones (estrogen, progestins, oral contraceptives),
 Danazol, anticoagulants, herbal or botanical supplements with possible hormonal
 effects. Washout will be allowed.

 5. Type I or Type II diabetes mellitus, or if receiving antidiabetic medications

 6. Significant anemia (Hemoglobin <8 g/dL).

 7. Untreated deep venous thrombosis, and/or pulmonary embolus

 8. Known heart disease (New York Heart Association Class II or higher).

 9. Known Liver disease (defined as Aspartate Aminotransferase (AST) or Alanine
 Aminotransferase (ALT)>2 times normal, or total bilirubin >2.5 mg/dL).

 10. Known Renal disease (defined as Blood urea nitrogen (BUN)>30 mg/dL or serum creatinine
 > 1.6 mg/dL).

 11. Clinically active autoimmune condition